Cuba's Black Market Medicines Rise as Pharmacies Stay Empty

What Happened

Official Cuban media has openly admitted to the rise of an informal market for medicines. This phenomenon is growing significantly through social media, Telegram channels, and street vendors.

It has become a desperate alternative for thousands of Cubans unable to find basic treatments in the state-run pharmacy system, which remains largely depleted.

Where and When

This situation is unfolding across Cuba as of March 2026. The scarcity is felt nationwide, prompting citizens in various provinces like Camagüey to seek illicit channels for vital medications.

The environment described is one of necessity, where the lack of available medicine in official outlets forces people into risky informal transactions, often on streets or online platforms.

Why It's Important

The increasing reliance on an unregulated black market highlights a critical failure in Cuba's public health system. It directly impacts patient safety, as drugs may lack proper storage or be of questionable origin.

For citizens, it means facing difficult choices between health and the risks associated with unofficial drug acquisition, underscoring the severity of the ongoing medication crisis.

What Parties Say

State media, like Periódico Trabajadores, now reports on the issue, describing the informal market as a "lifeline" for those without options. Citizens like Susana Iraola Fernández (71) admit resorting to street purchases out of sheer necessity.

Lázaro Marín, a medical student, notes vendors offering drugs without medical knowledge, increasing risks. Health authorities, including Cristina Lara Bastanzuri from MINSAP, acknowledge reliance on imports for 38% of basic medicines, while BioCubaFarma's VP, Santiago Dueñas Carrera, cites component shortages halting production.

What Comes Next

The situation suggests a continued struggle for access to essential medicines through official channels. The informal market is likely to persist as long as state shortages continue.

Citizens will likely continue to navigate these risky alternatives. Attention will remain on the government's ability to address production and import challenges affecting the national pharmaceutical supply.